Novartis AG (NVS)
109.56
2.04 (1.90%)
At close: Apr 14, 2025, 3:21 PM
1.90% (1D)
| Bid | 109.35 |
| Market Cap | 216.38B |
| Revenue (ttm) | 51.07B |
| Net Income (ttm) | 11.94B |
| EPS (ttm) | 5.87 |
| PE Ratio (ttm) | 18.66 |
| Forward PE | 12.31 |
| Analyst | Hold |
| Ask | 109.94 |
| Volume | 1,751,319 |
| Avg. Volume (20D) | 2,486,534 |
| Open | 107.20 |
| Previous Close | 107.52 |
| Day's Range | 107.08 - 109.62 |
| 52-Week Range | 92.35 - 120.92 |
| Beta | 0.55 |
About NVS
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops,...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Nov 7, 1996
Employees 75,883
Stock Exchange NYSE
Ticker Symbol NVS
Website https://www.novartis.com
Analyst Forecast
According to 6 analyst ratings, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $121, which is an increase of 10.45% from the latest price.
Stock ForecastsNext Earnings Release
Novartis AG is scheduled to release its earnings on Apr 29, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 days ago
+3.98%
Novartis shares are trading higher after the compa...
Unlock content with
Pro Subscription
5 months ago
-4.41%
Novartis shares are trading lower. The company reported Q3 financial results
